Microt

About Microt

Microt is a South Korean medical device company founded in 2019 that specializes in developing and manufacturing implants for glaucoma treatment. The company aims to provide safe and reliable treatment alternatives to assist medical staff and patients, addressing the world's second leading cause of blindness.

The company's main product is the A-stream® Glaucoma Shunt, a micro-invasive glaucoma surgery (MIGS) implant designed to control intraocular pressure (IOP). This device is a 6mm silicone tube with a 100µm inner diameter and a 1mm wing to hold it in place. It features a pre-placed ripcord that allows for adjustable flow control, aiming to reduce early hypotony and enable stepwise postoperative IOP adjustments. A short-term study showed that the A-stream shunt effectively lowered IOP with high success rates. Microt also offers Blecure MD Gel for dry and damaged periocular skin.

Since its establishment, Microt has achieved several milestones, including the completion of its Series A and B funding rounds. By July 2025, the company had raised a total of $13.7M. The company has received multiple accolades, including being selected as a "Baby Unicorn" company by the South Korean Ministry of SMEs and Startups. Its A-stream Glaucoma Shunt has received Korean MFDS (Ministry of Food and Drug Safety) approval and is approved for reimbursement under the Korean National Health Insurance. As of early 2025, the A-stream shunt had surpassed 1,500 surgical cases.

Microt operates in the surgical devices market and is headquartered in Seoul, South Korea. The company has formed research collaborations with institutions like KAIST, Sungkyunkwan University, and Chungbuk National University to advance its core technology. Its investors include Comes Investment, Horizon Investment, ID Ventures, Industrial Bank of Korea, and Samsung Medical Center.